ClinicalTrials.gg
RecruitingNCT07109895Updated Oct 9, 2026

Custom Insole With Transcutaneous Electrical Nerve Stimulation on Clinical Outcomes of Diabetic Foot Ulcers

An interventional study of Standard Care Only and Custom Insole + Standard Care in Diabetic Foot Ulcer, sponsored by University of Lahore. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Lahore · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 9, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Diabetic Foot with a site in Pakistan — 5 open to participants now, 7 under way, 1 of them phase 3. Diabetic Foot · Pakistan.

Planned enrollment
3rd of 16
159 · median 94
Started
2025
with 1 other
No phase
14 of 17
3 open now
Registered
11th of 17
by date

Among the 17 studies in Diabetic Foot with a site in Pakistan, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 11th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

5 of the 17 studies in Diabetic Foot with a site in Pakistan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetic Foot with a site in Pakistan, or all of them as a file.
02

Study summary

Diabetic foot ulcers (DFUs) are one of the serious complications of diabetes, typically resulting from neuropathy or peripheral arterial disease, and can often lead to amputation. It affects approximately 6.3% of people with diabetes globally. In Pakistan, the overall prevalence of DFUs is 16.83%, with a slightly higher rate in females. Diabetic foot ulcers are the main reason for lower extremity amputation (LEA) with non-traumatic origin, hospitalization, healthcare costs, and mortality.

Read the detailed description

Diabetic foot ulcers (DFUs) are a significant complication of diabetes, carry a high risk of amputation and disability, and affect around 6.3% of diabetic patients globally. Risk factors for DFUs include pre-ulcerative lesions, mechanical pressure, restricted mobility, and poor glycemic control. Peripheral neuropathy plays a crucial role in DFU development, causing structural and functional changes in the foot.

Offloading interventions, such as prefabricated orthotics and custom insoles, are essential for preventing DFU development and promoting ulcer healing. Physiotherapy modalities like therapeutic exercise and electrotherapy can assist in tissue repair and pain management. Orthotic management complements rehabilitation efforts, potentially reducing the risk of wound development. Further research on the combined benefits of transcutaneous electrical nerve stimulation (TENS) and customized insoles for DFUs is necessary to enhance clinical outcomes.

03

Conditions studied

  • Diabetic Foot Ulcer

Keywords

  • Functional Disability
  • Diabetic Foot Ulcer
  • Transcutaneous Electrical Nerve Stimulation
  • Customized Insole
  • Pain
  • Dynamic Balance
  • Risk of Fall
  • Wound Size
  • Wound Depth
  • Diabetes
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old with type 1 and 2 diabetes
  2. Both Males and Females
  3. Having Foot ulcers in Grade 1 and Grade 2 according to the Wagner Classification

Exclusion criteria

Exclusion Criteria:

  1. History of amputation (proximal to the trans-metatarsal joint)
  2. Active or inactive Charcot foot
  3. Non-constructible peripheral vascular disease secondary to arteriosclerosis (AS)
  4. Leg length discrepancy
  5. The presence of any allergic condition of the skin,
  6. Chronic consumption of opioids,
  7. Use of a cardiac pacemaker,
  8. Major bone operation,
  9. Neurological illness, such as a vestibular disorder with a history of dizziness 10. Mental disorders, which might interfere with the assessment process

11. Dementia or impaired cognitive function

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
159 participants (estimated)

Study arms

  • Other
    Standard Care Only

    Participants will receive standard care for diabetic foot ulcers.

    Other: Standard Care Only

  • Experimental
    Custom Insole + Standard Care

    Participants will receive a custom insole along with standard care.

    Other: Custom Insole + Standard Care

  • Experimental
    TENS + Custom Insole + Standard Care

    Participants will receive TENS therapy, a custom insole, and standard care.

    Other: TENS + Custom Insole + Standard Care

Interventions

  • OtherStandard Care Only

    Standard care includes routine wound debridement, moist wound dressings infection control, glycemic management, vascular assessment, and patient education in line with international DFU management guidelines.

  • OtherCustom Insole + Standard Care

    The experimental group will receive customised polyethene foam insoles with a Poron top layer along with standard care.

  • OtherTENS + Custom Insole + Standard Care

    Participants in this group will receive a combination of transcutaneous electrical nerve stimulation (TENS), custom-made insole therapy, and standard care for diabetic foot ulcers (DFUs).

06

What researchers measure

Primary outcomes

  1. Wound Healing

    Patients will be assessed for ulcer dimensions by using a simple ruler method. Length and width will be noted using a simple ruler method.

    Time frame: Wound dimensions will be measured at baseline, and change in length and width will be measured at the 4th week, 8th week, and 12th week of the treatment session.

Secondary outcomes

  1. Risk of fall

    The Tinetti Scale will be used to measure the risk of fall. The final score of the scale is 28 points, and the interpretation is as follows: 25-28 = low risk of falls; 19-24 = moderate risk of falls; and \<19 = high risk of falls.

    Time frame: Risk of fall will be measured at baseline, and change in status will be measured at the 4th week, 8th week, and 12th week of the treatment session.

  2. Dynamic Balance:

    The time up and go (TUG) scale will be used for measuring dynamic balance. A time score of ≤10 seconds is considered normal, and a time of ≥14 seconds has been shown to indicate a high risk of falls.

    Time frame: Change in status of dynamic balance will be measured at 4th week, at 8th week and 12th week of treatment.

  3. Pain Intensity

    Pain intensity will be measured using a visual analogue scale. It is an 11-point scale where "0" indicates no pain and "10" indicates the worst possible pain.

    Time frame: Pain intensity will be measured at baseline, and change in pain intensity will be measured at 4th week, 8th week, and 12th week.

  4. Toe Muscle Strength

    The paper grip test (PGT) will be used to measure toe muscle strength.

    Time frame: Toe Muscle Strength will be measured at baseline, and change in strength will be measured at the 4th week, 8th week, and 12th week of the treatment session.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: Will be share after publication

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 16 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Jan 2026 → Dec 2026 and completion Jan 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartActual
Aug 10, 2025
Primary completionEst.
Dec 30, 2026was Jan 2026
CompletionEst.
Jun 30, 2027was Jan 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 30, 2026→Dec 30, 2026
Oct 9, 2026
Study completion
Jan 30, 2026→Jun 30, 2027
Oct 9, 2026
Enrollment
40→159
Oct 9, 2026
Eligibility
Maximum age 60 Years→none; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited≥ 18-60 years old with type 1 and 2 diabetes
Oct 9, 2026
Interventions
Removed TENS plus Standard Care. Arms removed: TENS + Standard Care
Oct 9, 2026
Primary outcomes
2 removed
What changed in the outcomes
  • RemovedPain IntensityTime frame: Pain intensity will be measured at baseline, and change in pain intensity will be measured at 4th week, 8th week, and 12th week.
  • RemovedDynamic Balance:Time frame: Change in status of dynamic balance will be measured at 4th week, at 8th week and 12th week of treatment.
Oct 9, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedDynamic Balance:Time frame: Change in status of dynamic balance will be measured at 4th week, at 8th week and 12th week of treatment.
  • AddedPain IntensityTime frame: Pain intensity will be measured at baseline, and change in pain intensity will be measured at 4th week, 8th week, and 12th week.
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Jan 30, 2026→Dec 30, 2026
    Study completion Jan 30, 2026→Jun 30, 2027
    Enrollment 40→159
    Eligibility Maximum age 60 Years→none; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited≥ 18-60 years old with type 1 and 2 diabetes
    Primary outcomes 2 removed
    What changed in the outcomes
    • RemovedPain IntensityTime frame: Pain intensity will be measured at baseline, and change in pain intensity will be measured at 4th week, 8th week, and 12th week.
    • RemovedDynamic Balance:Time frame: Change in status of dynamic balance will be measured at 4th week, at 8th week and 12th week of treatment.
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedDynamic Balance:Time frame: Change in status of dynamic balance will be measured at 4th week, at 8th week and 12th week of treatment.
    • AddedPain IntensityTime frame: Pain intensity will be measured at baseline, and change in pain intensity will be measured at 4th week, 8th week, and 12th week.
    Interventions Removed TENS plus Standard Care. Arms removed: TENS + Standard Care
    + 3 other changes: index terms, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07109895
Responsible party
Ayesha Jamil (Assistant Professor, University of Lahore) — Principal investigator
First posted
Aug 7, 2025
Start date
Aug 10, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Ayesha Jamil, M.Phil Physiotherapy
Contact
ayeshabutt031@gmail.com
+92 324 4481031
Maryam Shabbir, PhD Rehabilitation
Contact
maryam.shabbir@uipt.uol.edu.pk
+92 300 4391550
Prof. Dr. Ashfaq Ahmed, PhD Physiotherapy
study director · University of Lahore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion